Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer

Habibollah Dadgar, Ali Pashazadeh, Nasim Norouzbeigi, Majid Assadi, Batool Al-Balooshi, Richard P. Baum, Akram Al-Ibraheem, Mohamad Haidar, Mohsen Beheshti, Parham Geramifar, Reza Vali, Seyed Mohammadi, Swagat Dash, Vindhya Malasani, Andrea Cimini, Maria Ricci, Abdulredha A. Esmail, Sarah Murad, Fahad Marafi, Giorgio TregliaAysar Najeh Khalaf, Farah M. Anwar, Sharjeel Usmani, Yehia Omar, Haider Muhsin, Igore E. Tyurin, Andrew Zakhary, Sahar Al-Sebaie, Danny Mena Cortes, Maryam AlHashim, Hossein Arabi, Habib Zaidi*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

15 Downloads (Pure)

Abstract

Radioligand therapy (RLT) has garnered significant attention due to the recent emergence of innovative and effective theranostic agents, which showed promising therapeutic and prognostic results in various cancers. Moreover, understanding the interaction between different types of radiation and biological tissues is essential for optimizing therapeutic interventions These concepts directly apply to clinical RLTs and play a crucial role in determining the efficacy and toxicity profile of different radiopharmaceutical agents. Personalized dosimetry is a powerful tool that aids in estimating patient-specific absorbed doses in both tumors and normal organs. Dosimetry in RLT is an area of active investigation, as our current understanding of the relationship between absorbed dose and tissue damage is primarily derived from external-beam radiation therapy. Further research is necessary to comprehensively comprehend this relationship in the context of RLTs. In the present review, we present a thorough examination of the involvement of 177Lu/225Ac radioisotopes in the induction of direct and indirect DNA damage, as well as their influence on the initiation of DNA repair mechanisms in cancer cells of neuroendocrine tumors and metastatic prostate cancer. Current data indicate that high-energy α-emitter radioisotopes can directly impact DNA structure by causing ionization, leading to the formation of ionized atoms or molecules. This ionization process predominantly leads to the formation of irreparable and intricate double-strand breaks (DSBs). On the other hand, the majority of DNA damage caused by β-emitter radioisotopes is indirect, as it involves the production of free radicals and subsequent chemical reactions. Beta particles themselves can also physically interact with the DNA molecule, resulting in single-strand breaks (SSBs) and potentially reversible DSBs.

Original languageEnglish
JournalTheranostics
Volume15
Issue number10
Pages (from-to)4368-4397
ISSN1838-7640
DOIs
Publication statusPublished - 2025

Keywords

  • Lu
  • Ac.
  • DNA damage
  • dosimetry
  • Radiopharmaceutical therapies
  • theranostics

Fingerprint

Dive into the research topics of 'Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this